163 related articles for article (PubMed ID: 35476781)
1. Construction of an algorithm based on oncosis-related LncRNAs comprising the molecular subtypes and a risk assessment model in lung adenocarcinoma.
Chen H; Zhou C; Hu Z; Sang M; Ni S; Wu J; Pan Q; Tong J; Liu K; Li N; Zhu L; Xu G
J Clin Lab Anal; 2022 Jun; 36(6):e24461. PubMed ID: 35476781
[TBL] [Abstract][Full Text] [Related]
2. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
Wang J; Shu J
Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
[TBL] [Abstract][Full Text] [Related]
3. A novel algorithm for lung adenocarcinoma based on N6 methyladenosine-related immune long noncoding RNAs as a reliable biomarker for predicting survival outcomes and selecting sensitive anti-tumor therapies.
Yan Q; Hu B; Chen H; Zhu L; Lyu Y; Qian D; Shao G
J Clin Lab Anal; 2022 Sep; 36(9):e24636. PubMed ID: 35949000
[TBL] [Abstract][Full Text] [Related]
4. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
[TBL] [Abstract][Full Text] [Related]
5. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.
Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z
Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892
[TBL] [Abstract][Full Text] [Related]
6. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
7. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
[TBL] [Abstract][Full Text] [Related]
8. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
9. Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs.
Chen H; Xu S; Hu Z; Wei Y; Zhu Y; Fang S; Pan Q; Liu K; Li N; Zhu L; Xu G
Medicine (Baltimore); 2022 Sep; 101(38):e30543. PubMed ID: 36197217
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients.
Shao J; Zhang B; Kuai L; Li Q
Bioengineered; 2021 Dec; 12(1):6186-6200. PubMed ID: 34486476
[TBL] [Abstract][Full Text] [Related]
11. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
12. A novel autophagy-related lncRNA survival model for lung adenocarcinoma.
Wu L; Wen Z; Song Y; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5681-5690. PubMed ID: 33987935
[TBL] [Abstract][Full Text] [Related]
13. Identification of an Autophagy-Related lncRNA Prognostic Signature and Related Tumor Immunity Research in Lung Adenocarcinoma.
Chen H; Hu Z; Sang M; Ni S; Lin Y; Wu C; Mu Y; Liu K; Wu S; Li N; Xu G
Front Genet; 2021; 12():767694. PubMed ID: 34956321
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
15. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
[TBL] [Abstract][Full Text] [Related]
16. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
18. A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
Wang L; Zhou SQ; Zhou Y; Lu JX
J Immunol Res; 2022; 2022():8069858. PubMed ID: 35600050
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
Jin D; Song Y; Chen Y; Zhang P
Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related IncRNAs in Lung Adenocarcinoma.
Shen Y; Hou N; Han F; Chen B; Shi J; Sun X
Crit Rev Eukaryot Gene Expr; 2022; 32(5):77-91. PubMed ID: 35993946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
